...Julika Dick; Alexander Enk; Jessica Cecile Hassel Ipilimumab, a monoclonal CTLA-4 antibody, was the first drug improving overall survival in patients with metastatic melanoma. However, there are still unanswered questions concerning therapeutic regimes, e.g. if maintenance therapy is needed...

... of sarcoidosis of 0.58% among melanoma inpatients. Clinicians should be aware of the possibility that sarcoidosis may initially manifest itself in melanoma patients, especially after treatment with immunotherapy, and mimic metastatic disease. Ipilimumab Interferon α Malignant melanoma Sarcoidosis...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Anti-CTLA4 monoclonal antibody Ipilimumab Melanoma Sarcoidosis Letter to Dermatology Published online: October 2...